

# John M Ringman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/205001/publications.pdf>

Version: 2024-02-01

82  
papers

8,865  
citations

147566

31  
h-index

91712

69  
g-index

88  
all docs

88  
docs citations

88  
times ranked

12220  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2012, 367, 795-804.	13.9	3,005
2	Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction. <i>Nature Medicine</i> , 2019, 25, 270-276.	15.2	987
3	Rare coding variants in PLCC2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. <i>Nature Genetics</i> , 2017, 49, 1373-1384.	9.4	783
4	APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. <i>Nature</i> , 2020, 581, 71-76.	13.7	705
5	Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2010, 3, 1.	3.0	424
6	Symptom onset in autosomal dominant Alzheimer disease. <i>Neurology</i> , 2014, 83, 253-260.	1.5	391
7	White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network. <i>Annals of Neurology</i> , 2016, 79, 929-939.	2.8	381
8	Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. <i>Neurology</i> , 2018, 91, e1295-e1306.	1.5	193
9	Functional Connectivity in Autosomal Dominant and Late-Onset Alzheimer Disease. <i>JAMA Neurology</i> , 2014, 71, 1111.	4.5	112
10	Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS). <i>Lancet Neurology</i> , The, 2016, 15, 1317-1325.	4.9	87
11	Effect of Potent $\beta$ -Secretase Modulator in Human Neurons Derived From Multiple Presenilin 1-Induced Pluripotent Stem Cell Mutant Carriers. <i>JAMA Neurology</i> , 2014, 71, 1481.	4.5	84
12	Mapping water exchange across the blood-brain barrier using 3D diffusion-prepared arterial spin labeled perfusion MRI. <i>Magnetic Resonance in Medicine</i> , 2019, 81, 3065-3079.	1.9	80
13	Preferential degradation of cognitive networks differentiates Alzheimer's disease from ageing. <i>Brain</i> , 2018, 141, 1486-1500.	3.7	79
14	Neuropathology of Autosomal Dominant Alzheimer Disease in the National Alzheimer Coordinating Center Database. <i>Journal of Neuropathology and Experimental Neurology</i> , 2016, 75, 284-290.	0.9	71
15	A probabilistic atlas of human brainstem pathways based on connectome imaging data. <i>NeuroImage</i> , 2018, 169, 227-239.	2.1	71
16	Genetic Heterogeneity in Alzheimer Disease and Implications for Treatment Strategies. <i>Current Neurology and Neuroscience Reports</i> , 2014, 14, 499.	2.0	70
17	CSF progranulin increases in the course of Alzheimer's disease and is associated with sTREM2, neurodegeneration and cognitive decline. <i>EMBO Molecular Medicine</i> , 2018, 10, .	3.3	64
18	The A431E mutation in PSEN1 causing Familial Alzheimer's Disease originating in Jalisco State, Mexico: an additional fifteen families. <i>Neurogenetics</i> , 2006, 7, 277-279.	0.7	62

#	ARTICLE	IF	CITATIONS
19	Current and Emerging Pharmacological Treatment Options for Dementia. <i>Behavioural Neurology</i> , 2006, 17, 5-16.	1.1	60
20	Past, present and future role of retinal imaging in neurodegenerative disease. <i>Progress in Retinal and Eye Research</i> , 2021, 83, 100938.	7.3	60
21	Relationship between physical activity, cognition, and Alzheimer pathology in autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 1427-1437.	0.4	51
22	White matter hyperintensities and the mediating role of cerebral amyloid angiopathy in dominantly-inherited Alzheimer's disease. <i>PLoS ONE</i> , 2018, 13, e0195838.	1.1	51
23	Clinical Predictors of Severe Cerebral Amyloid Angiopathy and Influence of <i>APOE</i> Genotype in Persons With Pathologically Verified Alzheimer Disease. <i>JAMA Neurology</i> , 2014, 71, 878.	4.5	50
24	Locus coeruleus integrity is related to tau burden and memory loss in autosomal-dominant Alzheimer's disease. <i>Neurobiology of Aging</i> , 2022, 112, 39-54.	1.5	49
25	Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group. <i>PLoS ONE</i> , 2016, 11, e0152082.	1.1	45
26	Volumetric distribution of perivascular space in relation to mild cognitive impairment. <i>Neurobiology of Aging</i> , 2021, 99, 28-43.	1.5	45
27	A novel sensitive assay for detection of a biomarker of pericyte injury in cerebrospinal fluid. <i>Alzheimer's and Dementia</i> , 2020, 16, 821-830.	0.4	43
28	Decreased body mass index in the preclinical stage of autosomal dominant Alzheimer's disease. <i>Scientific Reports</i> , 2017, 7, 1225.	1.6	42
29	MarkVCID cerebral small vessel consortium: I. Enrollment, clinical, fluid protocols. <i>Alzheimer's and Dementia</i> , 2021, 17, 704-715.	0.4	42
30	What the Study of Persons At Risk for Familial Alzheimer's Disease Can Tell Us About the Earliest Stages of the Disorder: A Review. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2005, 18, 228-233.	1.2	37
31	A Multiancestral Genome-Wide Exome Array Study of Alzheimer Disease, Frontotemporal Dementia, and Progressive Supranuclear Palsy. <i>JAMA Neurology</i> , 2015, 72, 414.	4.5	37
32	Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimer's disease. <i>Brain</i> , 2019, 142, 1429-1440.	3.7	36
33	Mosaicism for Trisomy 21 in a Patient With Young-Onset Dementia. <i>Archives of Neurology</i> , 2008, 65, 412-5.	4.9	35
34	Assessing intracranial vascular compliance using dynamic arterial spin labeling. <i>NeuroImage</i> , 2016, 124, 433-441.	2.1	35
35	Attitudes toward clinical trials across the Alzheimer's disease spectrum. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 81.	3.0	33
36	Use of the MoCA in Detecting Early Alzheimer's Disease in a Spanish-Speaking Population with Varied Levels of Education. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2015, 5, 85-95.	0.6	31

#	ARTICLE	IF	CITATIONS
37	Patient and caregiver reactions to clinical amyloid imaging. <i>Alzheimer's and Dementia</i> , 2017, 13, 924-932.	0.4	30
38	Comparison Between Blood-Brain Barrier Water Exchange Rate and Permeability to Gadolinium-Based Contrast Agent in an Elderly Cohort. <i>Frontiers in Neuroscience</i> , 2020, 14, 571480.	1.4	30
39	Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease. <i>Neurology</i> , 2015, 85, 790-798.	1.5	27
40	Regional association of pCASL-MRI with FDG-PET and PiB-PET in people at risk for autosomal dominant Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2018, 17, 751-760.	1.4	27
41	Seizures as an early symptom of autosomal dominant Alzheimer's disease. <i>Neurobiology of Aging</i> , 2019, 76, 18-23.	1.5	27
42	Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study. <i>Lancet Neurology</i> , The, 2021, 20, 615-626.	4.9	26
43	Evaluation of Cerebral Blood Flow Measured by 3D PCASL as Biomarker of Vascular Cognitive Impairment and Dementia (VCID) in a Cohort of Elderly Latinx Subjects at Risk of Small Vessel Disease. <i>Frontiers in Neuroscience</i> , 2021, 15, 627627.	1.4	25
44	A probabilistic atlas of locus coeruleus pathways to transentorhinal cortex for connectome imaging in Alzheimer's disease. <i>NeuroImage</i> , 2020, 223, 117301.	2.1	24
45	Autosomal dominant and sporadic late onset Alzheimer's disease share a common <i>in vivo</i> pathophysiology. <i>Brain</i> , 2022, 145, 3594-3607.	3.7	20
46	1H MRS spectroscopy in preclinical autosomal dominant Alzheimer disease. <i>Brain Imaging and Behavior</i> , 2019, 13, 925-932.	1.1	17
47	The "Alzheimer's Type" Profile of Semantic Clustering in Amnesic Mild Cognitive Impairment. <i>Journal of the International Neuropsychological Society</i> , 2014, 20, 402-412.	1.2	16
48	Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease. <i>Neurology</i> , 2021, 96, e1632-e1645.	1.5	16
49	Comparing amyloid- $\beta^2$ plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease. <i>Acta Neuropathologica</i> , 2021, 142, 689-706.	3.9	15
50	Cerebroarterial pulsatility and resistivity indices are associated with cognitive impairment and white matter hyperintensity in elderly subjects: A phase-contrast MRI study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 670-683.	2.4	14
51	A mixed-methods study of cultural beliefs about dementia and genetic testing among Mexicans and Mexican-Americans at risk for autosomal dominant Alzheimer's disease. <i>Journal of Genetic Counseling</i> , 2019, 28, 921-932.	0.9	12
52	Daily Activity Abilities in MCI, Alzheimer's Disease, and Healthy Controls. <i>GeroPsych: the Journal of Gerontopsychology and Geriatric Psychiatry</i> , 2015, 28, 191-200.	0.2	12
53	A survey of attitudes toward clinical trials and genetic disclosure in autosomal dominant Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 50.	3.0	10
54	A comparison of theoretical and statistically derived indices for predicting cognitive decline. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 6, 171-181.	1.2	10

#	ARTICLE	IF	CITATIONS
55	Update on Alzheimer's™s and the Dementias. <i>Neurologic Clinics</i> , 2017, 35, 171-174.	0.8	10
56	Lower retinal capillary density in minimal cognitive impairment among older Latinx adults. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12071.	1.2	10
57	Probing Estrogen Sulfotransferase-Mediated Inflammation with [11C]-PiB in the Living Human Brain. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 1023-1033.	1.2	10
58	Homozygosity for the A431E mutation in PSEN1 presenting with a relatively aggressive phenotype. <i>Neuroscience Letters</i> , 2019, 699, 195-198.	1.0	8
59	Reaction time and response inhibition in autosomal dominant Alzheimer's™s disease. <i>Brain and Cognition</i> , 2021, 147, 105656.	0.8	7
60	Cerebral Amyloid Angiopathy-related Inflammation Presenting With a Cystic Lesion in Young-onset Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2021, 35, 265-268.	0.6	5
61	“My backpack is so heavy” Experiences of Latino caregivers of family with <sc>early-onset</sc> Alzheimer's. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 1539-1547.	1.3	5
62	Different rates of cognitive decline in autosomal dominant and late-onset Alzheimer disease. <i>Alzheimer's and Dementia</i> , 2022, 18, 1754-1764.	0.4	4
63	Lower MRI-indexed locus coeruleus integrity in autosomal-dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e047676.	0.4	3
64	Enhanced Association of Tau Pathology and Cognitive Impairment in Mild Cognitive Impairment Subjects with Behavior Symptoms. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 557-568.	1.2	3
65	Are Late-Onset Autosomal Dominant and Sporadic Alzheimer Disease “Separate but Equal”? <i>JAMA Neurology</i> , 2016, 73, 1060.	4.5	2
66	Alzheimer and the Dementias. <i>Neurologic Clinics</i> , 2017, 35, ix-x.	0.8	2
67	Emotional detachment, gait ataxia, and cerebellar dysconnectivity associated with compound heterozygous mutations in the <i>SPG7</i> gene. <i>Neurocase</i> , 2020, 26, 299-304.	0.2	2
68	Alteration of perivascular spaces in early cognitive decline. <i>Alzheimer's and Dementia</i> , 2020, 16, e045605.	0.4	2
69	Patterns and implications of neurological examination findings in autosomal dominant Alzheimer disease. <i>Alzheimer's and Dementia</i> , 0, , .	0.4	2
70	[P2“489]: TOWARD AUGMENTING THE UNDERSTANDING OF GENETICS IN MEXICANS AT RISK OF AUTOSOMAL DOMINANT ALZHEIMER DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P827.	0.4	0
71	[P1“542]: CULTURAL BELIEFS ABOUT ALZHEIMER'S DISEASE IN MEXICAN AND MEXICAN-AMERICAN FAMILIES WITH AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P500.	0.4	0
72	[O1“02“04]: CLINICAL RISK RELATED TO CEREBRAL MICROHEMORRHAGES IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE: LONGITUDINAL RESULTS FROM THE DIAN STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P186.	0.4	0

#	ARTICLE	IF	CITATIONS
73	P4â€131: ATTITUDES TOWARD GENETIC TESTING AND CLINICAL TRIALS IN MEXICAN FAMILIES AT RISK OF AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1489.	0.4	0
74	P3â€276: PYRAMIDAL SIGNS IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1183.	0.4	0
75	P2â€100: IMPACT OF HYPERTENSION ON INTRACRANIAL ARTERIAL COMPLIANCE IN A LATINO COHORT. Alzheimer's and Dementia, 2018, 14, P706.	0.4	0
76	P2â€278: TRANSCALLOSAL CONDUCTION AND CENTRAL MOTOR CONDUCTION IN PEOPLE WITH A FAMILY HISTORY OF AUTOSOMALâ€DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P785.	0.4	0
77	Neuropsychiatric symptoms in early stage autosomal dominant and sporadic Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e044427.	0.4	0
78	Neurodegenerative substrate of behavioral changes in Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e045033.	0.4	0
79	The Spanish and english NIH Toolbox in autosomal dominant Alzheimerâ€™s disease: A preliminary report. Alzheimer's and Dementia, 2020, 16, e046752.	0.4	0
80	Historical Migration revealed through a Case of Autosomal Dominant Alzheimer's Disease. Puerto Rico Health Sciences Journal, 2019, 38, 144-147.	0.2	0
81	Differential correlation of white matter hyperintensity with Alzheimerâ€™s pathology within A/T groups. Alzheimer's and Dementia, 2021, 17, .	0.4	0
82	The relationship between bloodâ€brain barrier permeability and cerebral blood flow in cognitive impairment. Alzheimer's and Dementia, 2021, 17, .	0.4	0